In recent decades, there has been a steady increase in the incidence of malignant skin tumors worldwide. The number of HIV-infected patients is also increasing every year. Due to the evidence of a more aggressive course, increased occurrence of some skin cancers in HIV-infected patients, and the influence of immunosuppressive conditions on the clinical course of skin neoplasms, the study of these issues is a very relevant and promising direction in oncology and dermatovenerology.

THE OBJECTIVES OF THE STUDY

Were to describe the incidence, features of the clinical course, and treatment of malignant skin tumors in HIV-associated patients. Literature search and analysis were conducted using the major foreign article aggregator www.pubmed.com, and the Russian-language version of the research was conducted at www.elibrary.ru. The main results of the study show that various immunosuppressive conditions may be risk factors for the occurrence of malignant skin tumors in adults; in HIV-infected patients, the risk of skin cancer is 3—5 times higher, with lymphoma, melanoma, Kaposi's sarcoma, squamous cell, and basal cell cancers being the most common; squamous cell skin cancer in HIV infected individuals manifests at a younger age and is associated with a high risk of local recurrence, metastasis, and mortality; basal cell cancer has more aggressive course, including distant metastasis, in contrast to immunocompetent patients; skin melanoma has a poorer prognosis and a lower overall survival rate. It is concluded that the cornerstone of the treatment of HIV-associated malignant skin tumors is the restoration of immune function with antiretroviral therapy, suppression of the virus, and prevention of additional immunosuppression. Complex treatment with antiviral and immunomodulatory agents in addition to antitumor treatment should be an important part of therapy in reducing the aggressiveness of the course of cancer in immunocompromised HIV-infected patients.